Tricyclic antidepressants and chlorpromazine antagonize the therapeutic effects of guanethidine
It does not replace those systems or override pathological processes that require medical treatment
Comprehensive economic evaluations are needed to assist in payer decision-making for off-label uses of Semaglutide, factoring in the cost against potential benefits
The paradigm shift that began with EMPA-REG OUTCOME and LEADER has led to SGLT2 inhibitors and GLP-1 RA being recognised not only in international diabetes guidelines, but also as an important consideration for patients with T2D in CVD prevention [28,29,30, 76, 77], HF [133,134,135] and CKD [41, 102] guidelines, where it has been suggested that these agents should be considered early in the course of diabetes management
Noctor, G., Queval, G., Mhamdi, A., Chaouch, S
References: Yakar, S et al., 40 YEARS OF IGF1: Insulin-like growth factors: actions on the skeleton (Jul 2018)